+

WO1999047670A1 - Proteines mammiferes a canal sodique - Google Patents

Proteines mammiferes a canal sodique Download PDF

Info

Publication number
WO1999047670A1
WO1999047670A1 PCT/GB1999/000838 GB9900838W WO9947670A1 WO 1999047670 A1 WO1999047670 A1 WO 1999047670A1 GB 9900838 W GB9900838 W GB 9900838W WO 9947670 A1 WO9947670 A1 WO 9947670A1
Authority
WO
WIPO (PCT)
Prior art keywords
sns
protein
sodium channel
sequence
variant
Prior art date
Application number
PCT/GB1999/000838
Other languages
English (en)
Inventor
David Thomas Grose
Caroline Anne Hick
Simon Nicholas Tate
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to EP99910530A priority Critical patent/EP1062334A1/fr
Priority to AU29463/99A priority patent/AU2946399A/en
Priority to JP2000536853A priority patent/JP2002508941A/ja
Publication of WO1999047670A1 publication Critical patent/WO1999047670A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to a novel voltage-gated sodium ion channel (herein “sodium channel”), nucleotides coding for it. vectors and host cells containing the same and methods of screening for modulators of said channel for the alleviation of pain and use in hypersensitivity pathologies.
  • sodium channel a novel voltage-gated sodium ion channel
  • vectors and host cells containing the same and methods of screening for modulators of said channel for the alleviation of pain and use in hypersensitivity pathologies.
  • Voltage-gated sodium channels are responsible for the rising phase of the action potential and as such, play a key role in mediating electrical activity in excitable tissues.
  • the sodium channel is activated in response to depolarisation of the membrane. This causes a voltage-dependent conformational change in the channel from a resting, closed conformation to an active conformation, the result of which increases the membrane permeability to sodium ions ( 1.2).
  • Voltage-gated sodium channels comprise a multi-subunit complex consisting of a large (230-270kDa) highly glycosylated alpha ( ⁇ ) subunit which is usually associated with one or two of the smaller beta (b) subunits (bl and b2) (3).
  • the alpha subunits of voltage-gated sodium channels form a large multigene family which has expanded over recent years and at least nine different genes have now been identified in mammals (4-10).
  • This alpha subunit consists of four homologous domains (DI-IV), each containing six potential ⁇ -helical transmembrane segments (SI-S6) which makeup the pore forming region. Domains critical for the function of the channel are highly conserved throughout the family of voltage-gated sodium channels.
  • b subunits appear to have a role in altering the kinetics of the sodium channel during activation and inactivation gating. Expression of the b subunits has been associated with an increase in peak current and a role in trafficking of the a subunit to the membrane ( 14 -17).
  • the most potent blocker of voltage gated sodium channels is the puffer fish toxin, tetrodotoxin. (TTX).
  • Sensory neurones of mammalian dorsal root ganglion (DRG) cells transmit sensory information from the periphery to the central nervous system and are known to express at least three distinct kinetic types of voltage-gated sodium currents.
  • the small diameter neurones co-express a rapidly inactivating, fast TTX-sensitive current and a slowly activating and inactivating TTX-resistant sodium current.
  • the larger diameter cells only express TTX-sensitive sodium currents which have intermediate activation and inactivation kinetics (19.20).
  • This electrophysiological analysis has now been supported by molecular distribution studies, which suggest that there is a dynamic expression of voltage-gated sodium channels in DRG neurones which can change during development, response to injury and upon exposure to inflammatory mediators (21-24).
  • the small diameter neurones are unmyelinated and are involved in the transmission of pain impulses, these are the so called c-fibres or nociceptive neurones (25).
  • anaesthetic, anticonvulsant and antiarrythmic drugs each with sodium channel blocking activity, can produce analgesia.
  • anaesthetic, anticonvulsant and antiarrythmic drugs each with sodium channel blocking activity, can produce analgesia.
  • sub-anaesthetic doses of lignocaine and bupivocaine elevate pain thresholds in man (31.32).
  • anticonvulsant agents, phenytoin. carbamazepine and the class la antiarrythmic agent mexilitene are used clinically for neuropathic pain (33-35).
  • the anticonvulsant lamotrigine is also weakly analgesic (36).
  • This invention provides a novel voltage-gated sodium channel specifically found in the small diameter subset of mammalian sensory neurones.
  • This novel channel will be termed sensory neurone specific 2a (SNS 2a ).
  • SNS 2a sensory neurone specific 2a
  • the term "SNS 2a" as referred hereinafter will principally mean rat SNS 2a but may also be reference to the human form of the channel.
  • SNS 2a rat cDNA SEQ.I.D.NOJ
  • SNS 2a contains four homologous repeat domains each comprising six putative membrane spanning segments.
  • a serine residue S-355 is found at the site critical for TTX sensitivity and based on experiments with SNS/PN3. this residue should confer TTX resistance on clone SNS 2a (37).
  • the predicted first intracellular loop region connecting the first and second repeat domains is considerably shorter than the corresponding region in many of the other voltage-gated sodium channels including SNS/PN3. the cardiac channel and the brain channels.
  • Computer generated alignment of SNS 2a against the other members of the voltage-gated sodium channel gene family shows this ion channel to be distinct from anv of the channels identified to date. 4
  • One aspect of the invention therefore provides an isolated mammalian sensory neurone sodium channel protein as set forth in SEQ.I.D.NO:2.
  • the sodium channel of the invention is found in the neurones of the dorsal root ganglia.
  • the sodium channel protein may be derived from any mammalian species, preferably the rat or human.
  • variants of the sodium channel SNS 2a include fragments, analogues, derivatives, and splice variants.
  • variants refers to a protein or part of a protein which retains substantially the same biological function or activity as SNS 2a .
  • Fragments can include a part of SNS 2a which retains sufficient identity of the original protein to be effective for example in a screen. Such fragments may be probes such as the ones described hereinafter for the identification of the full length protein. Fragments may be fused to other amino acids or proteins (so-called "fusion' " proteins) or may be comprised within a larger protein. Such a fragment may be comprised within a precursor protein designed for expression in a host. Therefore in one aspect the term fragment means a portion or portions of a fusion protein or polypeptide derived from SNS 2a .
  • Fragments also include portions of SNS 2a characterised by structural or functional attributes of the protein. These may have similar or improved chemical or biological activity or reduced side-effect activity.
  • fragments may comprise an alpha helix or alpha -helix forming region, beta sheet and beta-sheet forming region, turn and turn forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, amphipathic regions (alpha or beta), flexible regions, surface- forming regions, substrate binding regions and regions of high antigenic index.
  • Derivatives include naturally occurring allelic variants.
  • An allelic variant is an alternate form of a protein sequence which may have a substitution, deletion, insertion rearrangment or addition of one or more amino acids, which does not substantially alter the function of the protein.
  • Derivatives can also be non-naturally occurring proteins or fragments in which a number of amino acids have been substituted, deleted or added.
  • Proteins or fragments which have at least 70% identity to SNS 2a are encompassed within the invention.
  • the identity is at least 80%, more preferably at least 90% and still more preferably at least or greater than 95% identity for example 97%. 98% or even 99% identity to SNS 2a .
  • Analogues include but are not limited to precursor proteins which can be activated by cleavage of the precursor portion to produce an active mature protein or a fusion with a compound such as polyethylene glycol or a leader/secretory sequence to aid purification.
  • a splice variant is a protein product of the same gene, generated by alternative splicing of mRNA. that contains additions or deletions within the coding region (Lewin N (1995) Genes V Oxford University Press. Oxford. England).
  • the present invention provides splice variants of the SNS 2a sodium channel that occur naturally and which may play a role in changing the activation threshold of the sodium channel.
  • the protein or variant of the present invention may be a recombinant protein. a natural protein or a synthetic protein. preferably a recombinant protein.
  • a further aspect of the invention provides an isolated and/or purified nucleotide sequence e.g. DNA or RNA which encodes a mammalian sodium channel as described above, or a variant thereof. Also included within the invention are anti- sense nucleotides or complementary strands.
  • the nucleotide sequence encodes a rat or human sodium channel.
  • the nucleotide sequence may comprise the sequence of the coding portion of the nucleotide sequence shown in SEQ.I.D.NO: 1.
  • a nucleotide sequence encoding a sodium channel of the present invention may be obtained from a cDNA or a genomic library derived from mammalian sensory neurones, preferably dorsal root ganglia.
  • the nucleotide sequence may be isolated from a mammalian cell (preferably a human cell), by screening with a probe derived from the rat or human sodium channel sequence, or by other methodologies known in the art such as polymerase chain reaction (PCR) for example on genomic DNA with appropriate oligonucleotide primers derived from or designed based on the rat or human sodium channel sequence and/or relatively conserved regions of known voltage-gated sodium channels.
  • PCR polymerase chain reaction
  • a bacterial artificial chromosome library (BAC) can be generated using rat or human DNA for the purposes of screening.
  • the nucleotide sequences of the present invention may be in form of RNA or in the form of DNA.
  • DNA includes cDNA, genomic DNA. and synthetic DNA.
  • the DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand.
  • the coding sequence which encodes the sodium channel or variant thereof may be identical to the coding sequence set forth in the SEQ.I.D NO: 1. or may be a different coding sequence which as a result of the redundancy or degeneracy of the genetic code, encodes the same protein as the sequences set forth therein.
  • a nucleotide sequence which encodes an SNS 2a sodium channel may include: a coding sequence for the full length protein or any variant thereof: a coding sequence for the full length protein or any variant thereof and additional coding sequence such as a leader or secretory sequence or a proprotein sequence: a coding sequence for the full length protein or any variant thereof (and optionally additional coding sequence) and non-coding sequences, such as introns or non-coding sequences 5 * and/or 3 " of the coding sequence for the full length protein.
  • the invention also provides nucleotide variants, analogues, derivatives and fragments which encode SNS 2a .
  • Nucleotides are included which preferably have at least 70% identity over their entire length to SNS 2j . More preferred are those sequences which have at least 80% identity over their entire length to SNS 2a . Even more preferred are polynucleotides which demonstrate at least 90% for example 95%. 97%. 98% or 99% identity over their entire length to SNS 2a .
  • the present invention also relates to nucleotide probes constructed from the nucleotide sequences of an SNS 2a sodium channel protein or variant thereof. Such probes could be utilised to screen a dorsal root ganglia cDNA or genomic library to isolate a nucleotide sequence encoding an SNS 2a sodium channel.
  • the nucleotide probes can include portions of the nucleotide sequence of the SNS 2a sodium channel or variant thereof useful for hybridising with mRNA or DNA in assays to detect expression of the SNS 2a sodium channel or localise its presence on a chromosome using for example fluorescence in situ hybridisation (FISH) as described in the examples.
  • FISH fluorescence in situ hybridisation
  • nucleotide sequences of the invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the protein of the present invention such as hexa-histidine tag or a hemagglutinin (HA) tag or allows determination in screening assays of effective blockage of SNS 2a or its modulation.
  • a marker sequence which allows for purification of the protein of the present invention such as hexa-histidine tag or a hemagglutinin (HA) tag or allows determination in screening assays of effective blockage of SNS 2a or its modulation.
  • Hybridisation is preferably under stringent hybridisation conditions.
  • stringent hybridisation conditions which is sometimes used is where attempted hybridisation is carried out at a temperature of from about 35°C to about 65°C using a salt solution which is about 0.9 molar.
  • the skilled person will be able to vary such conditions as appropriate in order to take into account variables such as probe length, base composition, type of ions present, etc.
  • the nucleotide sequences of the present invention may be employed for producing the SNS 2a sodium channel protein or variant thereof by recombinant techniques.
  • the nucleotide sequence may be included in any one of a variety of expression vehicles or cloning vehicles, in particular vectors or plasmids for expressing a protein.
  • vectors include chromosomal, non-chromosomal and synthetic DNA sequences.
  • suitable vectors include derivatives of bacterial plasmids: phage DNA: yeast plasmids; vectors derived from combinations of plasmids and phage DNA and viral DNA.
  • any other plasmid or vector may be used as long as it is replicable and viable in the host.
  • the present invention also provides recombinant constructs comprising one or more of the nucleotide sequences as described above.
  • the constructs comprise an expression vector, such as a plasmid or viral vector into which a sequence of the invention has been inserted, in a forward or reverse orientation.
  • the construct further comprises one or more regulatory sequences to direct mRNA synthesis, including, for example, a promoter, operably linked to the sequence. Suitable promoters include: CMV. LTR or SV40 promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses.
  • the expression vector may contain an enhancer and a ribosome binding site for translation initiation and transcription terminator.
  • Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts include mammalian expression vectors, insect expression vectors, yeast expression vectors, bacterial expression vectors and viral expression vectors and are described in Sambrook et al.. Molecular Cloning: A Laboratory Manual. Second Edition. Cold Spring Harbor. NY.. (1989).
  • a preferred vector is pBK-CMV.
  • the vector may also include appropriate sequences for selection and/or amplification of expression.
  • the vector will comprise one or more phenotypic 9 selectable/ampiifiable markers. Such markers are also well known to those skilled in the art.
  • the present invention provides host cells capable of expressing a nucleotide sequence of the invention.
  • the host cells can be. for example, a higher eukaryotic cell, such as mammalian cell or a lower eukaryotic cell, such as a yeast cell or a prokaryotic cell such as a bacterial cell.
  • Suitable prokaryotic hosts for transformation include E-coli.
  • Suitable eukaryotic hosts include HEK293 cells.
  • Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
  • the SNS 2a a sodium channel protein is recovered and purified from recombinant cell cultures by methods known in the art. including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography. phosphocellulose chromatography and lectin chromatography. Protein refolding steps may be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.
  • HPLC high performance liquid chromatography
  • the proteins and nucleotides sequences of the present invention are preferably provided in an isolated form.
  • isolated means that the material is removed from its original environment (e.g.. the naturally-occurring nucleotide sequence or protein present in a living animal is not isolated, but the same nucleotide sequence or protein. separated from some or all of the materials it co-exists with in the natural system, is isolated).
  • nucleotide sequence could be part of a vector and/or such nucleotide sequence or protein could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
  • proteins and nucleotides sequences of the present invention are also preferably provided in purified form, and preferably are purified to at least 50% purity, more preferably about 75% purity, most preferably 90% purity or greater such as 95%. 98% pure. 10
  • the present invention also provides antibodies specific for the SNS 2a sodium channel.
  • antibody as used herein includes all immunoglobulins and fragments thereof which contain recognition sites for antigenic determinants of proteins of the present invention.
  • the antibodies of the present invention may be polyclonal or preferably monoclonal, may be intact antibody molecules or fragments containing the active binding region of the antibody, e.g. Fab or F(ab) 2
  • the present invention also includes chimeric. single chain and humanised antibodies and fusions with non- immunoglobulin molecules. Various procedures known in the an may be used for the production of such antibodies and fragments.
  • the proteins, their variants especially fragments, derivatives, or analogues thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto.
  • Antibodies generated against the SNS 2a sodium channel can be obtained by direct injection of the polypeptide into an animal, preferably a non-human mammal. The antibody so obtained will then bind the protein itself. In this manner, even a sequence encoding only a fragment of the protein can then be used to generate antibodies binding the whole native protein. Such antibodies can then be used to locate the protein in tissue expressing that protein.
  • the antibodies of the present invention may also be of interest in purifying an SNS 2a protein and accordingly there is provided a method of purifying an SNS 2a or any portion thereof which method comprises the use of an antibody of the present invention.
  • the present invention also provides methods of identifying modulators of the sodium channel. Screens can be established for SNS 2a enabling large numbers of compounds to be studied. High throughput screens may be based on l4 C guanidine flux assays and fluorescence based assays as described in more detail below. Secondary screens may involve electrophysiological assays utilising patch clamp technology or two electrode voltage clamp to identify small molecules, antibodies, peptides. proteins, or other types or compounds that inhibit, block, or otherwise interact with the sodium channel. Tertian' screens mav involve the studv of the modulators in well characterised rat and 1 1 mouse models of pain. These models of pain include, but are not restricted to. intra- plantar injection of inflammatory agents such as carageenan. formalin and complete freunds adjuvant (CFA). Models of neuropathic pain such as loose ligature of the sciatic nerve are also included.
  • CFA complete freunds adjuvant
  • the invention therefore provides a method of assaying for a modulator comprising contacting a test compound with the sodium channel and detecting the activity or inactivity of the sodium channel.
  • the methods of identifying modulators or screening assays employ transformed host cells that express the sodium channel.
  • such assays will detect changes in the activity of the sodium channel due to the test compound, thus identifying modulators of the sodium channel.
  • host cells expressing the sodium channel can be employed in ion flux assays such as :2 Na+ ion flux and l4 C guandinium ion assays, as described in the examples and in the art. as well as the SFBI fluorescent sodium incubator assays as described in Levi et al.. (1994) J Cardiovascular Electrophysiology 5_-241-257 and voltage sensing dyes such as DiBAC.
  • ion flux assays such as :2 Na+ ion flux and l4 C guandinium ion assays, as described in the examples and in the art.
  • SFBI fluorescent sodium incubator assays as described in Levi et al.. (1994) J Cardiovascular Electrophysiology 5_-241-257 and voltage sensing dyes such as DiBAC.
  • Host cells expressing the SNS 2a sodium channel can also be employed in binding assays such as the 3-H- batrachotoxin binding assay described in Sheldon et al., (1986) Molecular Pharmaeology 30:617- 623: the 3-H- saxitoxin assay as described in Rogart et al (1983) Proc Natl. Acad. Sci. USA 80: 1 106-1 1 10: and the scorpion toxin assay described in West et al.. (1992) Neuron 8: 59-70.
  • binding assays such as the 3-H- batrachotoxin binding assay described in Sheldon et al., (1986) Molecular Pharmaeology 30:617- 623: the 3-H- saxitoxin assay as described in Rogart et al (1983) Proc Natl. Acad. Sci. USA 80: 1 106-1 1 10: and the scorpion toxin assay described in West et al.. (1992) Neuro
  • test compound is added to the assay and its effect on sodium flux is determined or the test compound ' s ability to competitively bind to the sodium channel is assessed. Test compounds having the desired effect on the sodium channel are then selected.
  • Modulators of the sodium channel will impede or prevent the transmission of impulses along sensory neurones and thereby be useful in the treatment of acute. chronic or neuropathic pain i.e. production of an analgesic effect and or in the treatment of hypersensitivity pathologies.
  • Modulators of the present invention and 12 medicaments comprising the same may also be particularly useful in the the treatment of pain associated with inflammatory conditions e.g. arthritic conditions such as rheumatoid arthritis.
  • the invention therefore provides a modulator of a protein or a variant thereof as described above identifiable by a method described above for use in therapy.
  • the invention further provides the use of a modulator of a sodium channel protein optionally identifiable by a method described above for the manufacture of an analgesic or anti-hypersensitvity medicament.
  • medicaments are typically pharmaceutical compositions comprising an effective amount of the modulator together with stabilisers, preservatives and the like as known and called for by accepted pharmaceutical practice.
  • Effective amounts of the modulator i.e. therapeutically effective amounts, may be determined according to routine methods known to those skilled in the art.
  • the invention further provides a method of treatment which comprises administering to a patient an effective amount of a modulator of a protein as described above. Treatment protocol will depend on a number of considerations including the severity of the condition to be treated, such considerations being within the purview of the attending physician.
  • Modulators of the present invention may also be used in conjunction with e.g. simultaneously. sequentially or separately with modulators of the ion channel disclosed in
  • Complementary or anti-sense strands of the nucleotide sequences as hereinabove defined can be used in gene therapy.
  • the cDNA sequence or fragments thereof could be used in gene therapy strategies to down regulate the sodium channel.
  • Antisense technology can be used to control gene expression through triple-helix formation of antisense DNA or RNA. both of which methods are based on binding of a nucleotide sequence to DNA or RNA.
  • a DNA oligonucleotide is designed to be complimentary to a region of the gene involved in transcription thereby preventing transcription and the product of the sodium channel.
  • the antisense RNA olignucleotide hvbridises to the mRNA in vivo 13 and blocks translation of the mRNA into the sodium channel.
  • Antisense oligonucleotides or an antisense construct driven by a strong constitutive promoter expressed in the target sensory neurons would be delivered either peripherally or to the spinal cord, optionally by minimally invasive e.g. endoscopic. means.
  • the regulatory regions controlling expression of the sodium channel gene could be used in gene therapy to control expression of a therapeutic construct in cells expressing the sodium channel.
  • a protein which has a primary amino acid sequence with at least 90% or greater identity with the primary amino acid sequence of the protein of SEQ.I.D.NO.2.
  • a recombinant polynucleotide comprising a sequence which comprises the sequences as defined in each of SEQ.l.D. NO:3 to 17 wherein ascending numerical order represents the order in which the SEQ.l.D. NO:3 to 17 is read in the 5' to 3' direction.
  • the recombinant polynucleotide may further comprise sequences spaced before, between and after the sequences (in terms of reading direction) defined in SEQ.I.D.NO:3 to 17 such that when the polynucleotide is expressed in a host cell, e.g. mammalian cell, a functional sodium channel is encoded.
  • Figure 1 is a summary of the rat SNS a ion channel fragments isolated, and probes used for analvsis.
  • Figure 2 depicts the position of SEQ.l.D. NO:3 to SEQ.I.D.NO: 17 relative to the rat
  • Figure 3 shows the localisation of human SNS 2a to human chromosome 3p21.
  • Figure 4 shows rat multiple tissue Northern Blot probed with SNS 2a .
  • Figure 5 In situ hybridisation in rat DRG tissue using an SNS 2a specific probe.
  • Figure 5a) shows a sense probe and 5b) shows an anti-sense probe.
  • FIG. 6 shows localisation of SNS 2a to human DRG
  • FIG. 7 Northern blot probed with SNS 2a using DRG tissue taken from rat pain models.
  • Lane 1 Control DRG;
  • Lane 2 DRG + 24 hours complete freunds adjuvant (CFA):
  • Lane 3 DRG + 24 hours sciatic nerve cut:
  • Lane 4 DRG + 48 hours sciatic nerve cut;
  • Lane 5 DRG + 7 days sciatic nerve cut.
  • Figure 8 illustrates the three vectors into which rat SNS 2a has been cloned: pBluescript. pCI-neo and pCIN5.
  • Figure 9 shows photomicrographs of SNS 2a and SNS/PN3 staining for mRNA and protein.
  • D.E. F confirm SNS 2a labelling is found exclusively in small neurons (10- 25 ⁇ m diameter).
  • Double labelling for SNS 2a and SNS/PN3 mRNA and protein shows colocalisation in small neurons ( arrows); larger neurons can be seen positive for SNS/PN3 but negative for SNS 2a (arrowheads).
  • Figure 10 Immunoprecipitation Western blot showing specific staining in the lanes from cells transfected with SNS 2a DNA with the two antipeptide antibodies designed to SNS a . Control lanes, where cells were transfected with yellow fluorescent protein (YFP) show no staining. 15
  • Figure 11 shows biophysical and pharmacological properties of recombinant rat SNS 2a Na" channels expressed in HEK293T cells. Representative current records are shown along with their peak current-voltage relationships (A.B). Capacitance transients have been blanked for clarity. Pannel C illustrates the effect of TTX on SNS 2a . It is resistant to sub ⁇ M concentrations of TTX. compared with the nM sensitivity of TTX sensitive sodium channels.
  • a sodium channel probe was generated to allow screening of a rat DRG cDNA library with the aim to identify novel sodium channels present in the DRG.
  • a pan specific sodium channel probe was obtained from Polymerase chain reaction (PCR) experiments using rat genomic DNA as the template and degenerate PCR primers designed from within the 3 ' coding regions of the brain II. heart, skeletal muscle and glial voltage-gated sodium channel.
  • the oligonucleotide primers used for this analysis were as follows. FORWARD PRIMER (5 ' CCTG/CGTCATGTTCATCTAC 30 and REVERSE PRIMER (5 " CTCATAA/GGAA/GAC/TCTTGGAG/AGGG 3 " ).
  • the PCR conditions used, were 94°C for 30 seconds.
  • a rat DRG cDNA library was constructed in ⁇ ZAP ExpressTM Bacteriophage system
  • RNAzol B (Strategene). allowing it to be directionally cloned within the pBK-CMV excision vector. Briefly, lumbar DRG tissue was removed from adult rats and frozen in liquid nitrogen until ready for processing. Total RNA was extracted using RNAzol B
  • RNA was then isolated from the total RNA pool by oligo dT celluloise chromatography (invitrogen) as per manufacturers instructions. 5 ⁇ g of this poly (A+) rat DRG RNA was used as the starting template for cDNA library synthesis. This was carried out exactly as stated in the Stratagene Instruction manual for construction of a
  • ZAP express cDNA library using the Gigapack III Gold cloning kit.
  • SNS 2a has been assembled in the Sall/NotI sites of the mammalian expression vector pBluescript (Stratagene). the Sall/NotI sites of the mammalian expression vector pCI- neo (Promega). SNS 2a was also cloned into the Clontech IRES vector pIRESneo. the multiple cloning site of this vector was modified to include Nsil/Notl sites which were used for cloning SNS 2a in the correct orientation. This allows for both transient and stable expression studies in mammalian cells such as HEK293 cells (ATCC).
  • SEQ.l.D. NO: 1 Nucleotide sequence analysis of SEQ.l.D. NO: 1 reveals a 5298bp open reading frame which encodes a 1765 amino acid protein (SEQ.l.D. no.2). This deduced protein sequence shares many of the characteristic features associated with the voltage-gated sodium channel gene family, however, the predicted first intracellular loop region connecting the first and second repeat domains is considerably shorter than the corresponding region in many of the other voltage-gated sodium channels including SNS/PN3. the cardiac channel and the brain channels. 18
  • SEQ.l.D. NO: 1 Nucleotide sequence analysis of SEQ.l.D. NO: 1 reveals a 5298bp open reading frame which encodes a 1765 amino acid protein (SEQ.l.D. no.2). This deduced protein sequence shares many of the characteristic features associated with the voltage-gated sodium channel gene family, however, the predicted first intracellular loop region connecting the first and second repeat domains is considerably shorter than the corresponding region in many of the other voltage-gate
  • the DNA was transferred onto a GeneScreenTM hybridisation transfer membrane (DUPONT) by placing on the surface of the phage infected plate for 1 minute.
  • the membrane is washed with IM NaOH twice for 2 minutes, followed by two neutralisation steps in I M Tris (pH 7.4) for an additional 2 minutes. An additional duplicate lift was done with the filter on the plate for five minutes prior to the washing steps.
  • the membrane is then air dried overnight or crosslinked using the UV Stratalinker (Stratagene).
  • the membranes were hybridised for 4 hours shaking at 60°C in a 10% dextran sulphate, 1% lauryl sulphate (SDS) (see solutions and media) and IM NaCl solution.
  • the probes used were LARI & QFL and 18/14 respectively, from the 5 " and middle regions of 33b.
  • the probe was labelled with [cc 3 p ] dCTP (Amersham) using the RediprimeTM DNA labelling system (Amersham), so as to obtain approximately 500,000 cpm of the labelled probe per ml of prehybridization solution. Briefly. lOOng of each probe was boiled for 3 minutes (denaturization) and then cooled on ice for 2 minutes in a total volume of 45 ⁇ l.
  • the membranes were then washed, first at room temperature, in 2x SSC (3M sodium chloride and 0.3M sodium citrate pH7) and 1% SDS (sodium dodecyl sulphate) for 5 minutes, followed by 2x SSC and 1% SDS for 30 mins at 50°C. and if necessary further washes with lx SSC and 0.5% SDS or OJx SSC and 0.1 % SDS for 30 mins at 19 the same temperature. The membranes were then exposed to Scientific Imaging Film
  • PCR products which were separated using agarose gel electrophoresis were denatured in situ by shaking the gel slowly in 1.5M NaCl for 10 minutes followed by a 0.5M NaOH solution for 30 minutes.
  • DUPONT GeneScreenTM hybridization transfer membrane
  • phage plugs were removed from the agarose plate and placed in 500 ⁇ l of SM buffer. Elution of the phage particles occured at room temperature while gently shaking for 2-3 hours. 1 ⁇ l of ExAssistTM Helper phage (Stratagene) was added to lOO ⁇ l of phage stock in SM buffer (see media and solutions) and incubated at 37°C for 15 minutes. 3ml of liquid broth (see media and solutions) was added, followed by shaking at 225rpm at 37°C for 3 hours. Heat shock at 70°C for 15 minutes was followed by centrifugation at 4000rpm for 15 minutes at 4°C. The supernatant was carefully decanted into sterile 50ml falcon tube and stored at 4°C until needed.
  • lO ⁇ l and lOO ⁇ l of the rescued recombinant plasmid were used to transform 200 ⁇ l of XLOLR cells (Stratagene) at OD 600 1.0 and incubated at 37°C for 15 minutes. The samples are incubated for a further 45 minutes at 37°C 20 after the addition of 300 ⁇ l of L-broth (see media and solutions), followed by spreading on kan-plates ( 15 ⁇ g/ml) (see media and solutions) and incubation overnight at 37°C. Positive colonies were analysed by digest analysis using Xhol and EcoRI restriction enzymes followed by subsequent southern blot analysis.
  • Example 3 Transient expression of SNS ?1 in mammalian cells
  • HEK293 cells Mammalian cells such as HEK293 cells were plated 24 hours prior to transfection. such that they are 50-80% confluent for the transfection procedure. On the day of transfection fresh media was added to the cells.
  • the transfection protocol to be used relies upon the calcium phosphate transfection method (CalPhos maximer. Clontech) although any transient transfection method can be used. Briefly, a solution referred to as solution A. was made up containing 2-4 ⁇ g of plasmid DNA per 4 x 10' cells, 5 - 30 ⁇ l of CalPhos maximer, 12.4 ⁇ l 2M calcium solution, sterile water to 100 ⁇ l.
  • solution B was also made up comprising.
  • PC 12 cells (ATCC). and PC12 cells pretreated with NGF were electrophoresed on a 1% agarose gel. 21 containing 8% formaldehyde.
  • the preparation of the total RNA was carried out as described in the construction of the rat DRG cDNA library). The gel was then blotted onto a GenescreenTM membrane as described previously in Example Id and probed with the 18/14 probe as described in Example lc. Exposure to Kodak X-AR film occurred overnight.
  • SNS 2a The expression of SNS 2a in DRG tissue was studied in DRG tissue removed from two separate rat models of pain, namely the Complete Freunds Adjuvant (CFA) model and the sciatic nerve cut (axotomy) model.
  • CFA Complete Freunds Adjuvant
  • axotomy the sciatic nerve cut
  • the 18/14 probe which was specific to SNS 2a in northern blot analysis, was used to generate riboprobes.
  • the 18/14 probe was cloned into the vector pCR-II ( Invitrogen). Labelled RNA strands were transcribed in vitro from the vector promoters. SP6 and T7. using the DIG RNA labelling Kit (Boeringer Manheim). l ⁇ g ->-> linearised template DNA was used to produce 'run off transcripts. DIG-UTP was used as a substrate and incorporated into the transcript. The amount of DIG labelled RNA generated was determined using the DIG Quantification and Control Teststrips (Boehringer Manheim). DIG labelled sense and anti-sense RNA probes were used for in situ hybridisation to stain rat DRG sections (see section on antibody generation).
  • octadecapeptide CNGDLSSLDVAKVKVHND relating to amino acid residues 1748 to 1765 of SNS 2a
  • the peptide EERYYPVIFPDERNC relating to amino acid residues 2 to 15 of SNS 2a were synthesised on a Biosearch 9500 peptide synthesiser using solid-phase Fmoc chemistry under conditions recommended by the suppliers.
  • Cleaved peptide was purified by gel filtration and conjugated to purified protein derivative of tuberculin (PPD) using sulpho-SMCC.
  • Dutch rabbits, presensitised against BCG. were immunised with the resulting conjugate emulsified in incomplete Freunds adjuvant. Rabbits were boosted at three week intervals and serum prepared from test bleeds 7 days after each injection. The specific antibody response was followed by indirect ELISA using free synthetic peptide as antigen. High titre antisera were used for further studies.
  • anti-peptide antibodies directed to SNS 2a can be used in immunohistochemistry experiments.
  • Several fusion protein antibodies have also been generated against SNS 2a .
  • the PCR primers used to generate fusion peptides were as follows:
  • the anti-peptide antibodies have been verified by specific staining of recombinant SNS 2a expressed in HEK293 cells (see section on transient expression of SNS 2a ).
  • HEK293 cells were transfected with a) SNS 2a DNA or b) YFP. yellow fluorescent protein. DNA as a control. 48 hours after transfection whole cell lysates. prepared with RIPA. were precleared using non-immune rabbit IgG and protein-A-sepharose followed by centrifugation.
  • Immunoreactive proteins were then precipitated by adding specific antibodies to the resulting supematants. Dissolved precipitates were subjected to SDS-PAGE and immunoblotted using a cocktail of anti-SNS 2a antibodies. Bound immunoglobulins were revealed using HRP-labelled secondary antibodies and ECL detection. Anti-SNS 2a antibodies showed specific binding to cells transfected with SNS 2a DNA. confirming the specificity of the antibodies and the presence of SNS 2a protein (see figure 10).
  • the anti-peptide antibodies and riboprobes have been used for in situ hybridization and immunohistochemistry to stain rat DRG sections.
  • Fresh frozen L4 and L5 dorsal root ganglia from adult male Sprague Dawley rats were cut at 20 ⁇ m. air dried and fixed, acetylated and hybridised with 500ng/ml digoxygenin-labelled riboprobes (see section on SNS 2a riboprobes).
  • Sense probes were used as a control.
  • the sections were photographed before incubating overnight in either SNS/PN3 or SNS 2a antibody (1 :2000). Staining was achieved using a Vectastain elite ABC kit (Vector).
  • Double labelling studies for mRNA and protein in the same section showed co- localization only in small diameter neuronal cell bodies (figure 9. G.H.IJ). Large neurons were frequently seen with a signal for SNS/PN3 mRNA or protein where SNS 2a protein or mRNA were absent. The co-localisation of SNS 2a with SNS/PN3 in small diameter cell bodies may be functionally significant.
  • Antisense oligonucleotides were synthesised to further validate the contribution of SNS 2a to the TTX-R current in DRG neurons.
  • the antisense and mismatch oligos were designed to the 5 " region of the SNS 2a nucleotide sequence from base pair 45 to 180, the sequences were as follows:
  • the antisense oligonucleotides may be used in vitro w : ith cultured rat DRG neurons to look at the effects of knockdown of SNS 2a protein on the electrophysiological properties of the DRG neurons.
  • the behavioural effect of SNS 2a knockdown in rat DRG neurons maybe looked at in vivo using antisense delivery via cannulae into the spinal cord. Reduction of SNS2a protein levels maybe measured by quantitative western blots. A full electrophysiological analysis can then be carried out. This 25 permits analysis of the role of SNS 2a in normal nociception and in inflammatory and neuropathic pain models.
  • SNS 2a forms functional voltage-gated Na ⁇ channels when expressed in mammalian cells (e.g. HEK293T), as determined using whole-cell patch clamp electrophysiology.
  • evoked Na" currents ranged from -600pA to -4500pA and thus the maximum estimated voltage drop across the compensated series resistance will amount to less than 4mV.
  • Patch pipettes were fabricated from 1.5mm outside diameter borosilicate capillary glass (Clark Electromedical) using a micropipette puller (Sutter model P97). and fire polished (Narishige Microforge) to give final tip resistances of 2-4m ⁇ .
  • a silver/silver chloride pellet was used as the bath reference electrode and the potential difference between this and the recording electrode was adjusted for zero current flow before seal formation.
  • Cells were visualised using a Diaphot200 inverted microscope (Nikon) with modulation contrast optics at a final magnification of x400.
  • SNS 2a may be the prototypical member of a new gene family, related to both TTX-R and TTX-S sodium channels. Consistent with this. SNS 2a displays a combination of TTX resistance (IC50 for TTX in the ⁇ M range) and channel biophysical properties, more characteristic ofthe TTX-S channels.
  • SNS 2a encoded a functional voltage-gated sodium channel when expressed in HEK293T cells, which displayed more rapid activation and inactivation kinetics and a lower threshold for activation than seen for SNS/PN3 (see PCT/GB96/01523) expressed in the same cells.
  • Previous electrophysiological studies of small diameter DRG cells have provided data compatible with heterogeneity of the TTX-R current (Rizzo et al.. 1994: Rush and Elliott. 1997: Scholz et al.. 1998).
  • TTX-R current profiles varied between cells: in a few cells the TTX-R current 27 biophysical properties were similar to the profile expressed by SNS 2a in HEK293T cells and in a small group of others, the kinetics were more similar to the profile expressed by SNS/PN3.
  • TTX-R currents in DRG neurons that were activated at voltages as low as -60mV as was case for SNS 2a . This is consistent with our distribution data suggesting that SNS 2a is not found alone but is always expressed together with the higher threshold SNS/PN3 channel. In most cells. however, the current biophysical properties of TTX-R were intermediate between the two, suggesting that the current results from a combination of the activity of both
  • High throughput screens are based on assays such as C guanidine flux assays and fluorescence based assays using both sodium indicator dyes such as SBFI and voltage sensing dyes such as DiBAC.
  • Secondary screens involve electrophysiological assays utilising patch clamp technology or two electrode voltage clamp. Tertiary screens involve the study of modulators in rat and mouse models of pain.
  • the critical path depicting the key steps in the SNS 2a high throughput screen is shown below.
  • the screen should aim to cover at least 200.000 compounds in the primary screen but may be as high as 1 million compounds, the hit compounds are then re- tested against mammalian cell lines expressing the brain and/or cardiac sodium channels.
  • the tertiary screen will take compounds which are potent and selective and test them in a range of in-vivo pain models.
  • the G-FLUX method is the method of choice and it has been further improved with the introduction of Cytostar-T plates (Amersham) which remove the necessity for digestion of the cells in triton and transfer into scintillation vials.
  • Cytostar-T plates are standard format tissue culture treated plates in which the transparent base of each well is composed of polystyrene and scintillant that permits cultivation and observation of adherent cell monolayers. Radioisotopes brought in close proximity with the base by virtue of the biological process within the cells thereby result in the generation of light.
  • Mammalian cells stably over-expressing SNS 2a will be cultured in 96 well plates.
  • One T225cm 3 flask will be sufficient for setting up ten 96 well plates with a volume of lOO ⁇ l cell culture medium in each well. These plates are set up the night before each assay run.
  • the culture medium is removed and lOO ⁇ l of assay buffer (125mM Choline chloride. 50mM HEPES. 5.5mM Glucose. 0.8mM MgSO,. 5mM KC1. pH 7.4 added.
  • the test compounds are then added to the wells and pre-incubated for a period of 10 minutes.
  • Scorpion toxin (0.31 mg ml "1 ) and veratrine ( 1.25mg ml' (Sigma) will then be added to activate the sodium channel, these compounds hold the channel in a open conformation.
  • the cells are incubated for a further 10 minutes prior 29 to the addition of U C guanidine (Amersham). This is incubated for a period of 3 minutes after which time the whole plate can be read on a scintilation counter.
  • the human SNS 2a gene has been cloned as a genomic DNA fragment. PCR experiments were performed on human genomic DNA. using oligonucleotide primers designed from the rat SNS 2a sequence. A fragment corresponding to the human SNS 2a gene was subsequently isolated and sequenced. A human bacterial artificial chromosome (BAC) library (Research Genetics) was then screened using PCR primers designed from human sequence. A 120kb BAC clone (BAC#4) was isolated which has been extensively characterised following the construction of a random library from the BAC clone, (see section below). This clone contains the gene encoding human SNS 2a (SEQ.I.D.NO: 3 to 17) shows regions where coding sequence has been obtained from the BAC clone against an idealised template.
  • BAC#4 This BAC clone (BAC#4) containing human SNS 2a was mapped to human chromosome 3p21 by fluorescence in situ hybridisation (FISH) (figure 3).
  • FISH fluorescence in situ hybridisation
  • the human SNS/PN3 gene has also been mapped to the same chromosomal locus. It is worthy of note that the human cardiac channel has also been mapped to chromosome 3p21. A new gene cluster of TTX-resistant sodium channels has therefore been identified on human chromosome 3.
  • BAC DNA was purified according to the Qiagen BAC DNA method. Briefly BAC liquid culture was inoculated into a 5ml starter culture of L broth with 12.5 ⁇ g/ml chloramphenicol selection. This was used to inoculate 200 ml L broth with (selection) which was then grown for 14 hours at 37 C with vigorous shaking. The culture was then centrifuged at 4500 x g for 20 minutes. The bacterial pellet was resuspended in 20 ml of buffer pi . 20 ml of P2 was added and the solution was mixed gentlv and incubated at 21 C for 5 minutes 20 ml of chilled buffer P3 was added. 30 solution mixed gently and incubated on ice for 15 minutes. Following centrifugation at 20000 x g for 30 minutes the supernatant was applied to an equilibrated Qiagen Tip
  • the column was washed twice with 10 ml of buffer QC.
  • the DNA was eluted with five 1 ml aliquots of buffer QF, pre warmed to 65 C.
  • the DNA was precipitated with 3.5 ml of isopropanol and centrifuged at 15000 x g for 15 minutes. The supernatant was removed and the pellet was washed with 2 ml of 70% ethanol and centrifuged at 1500 x g for 10 minutes. The pellet was finally air dried for 10 minutes and resuspended in water.
  • the DNA was size selected with Pharmacia SizeSep 400 spin column.
  • the resulting DNA fragments were ligated into a Smal phosphatased pBluescript II SK vector (Stratagene) and subsequently transformed into XL1 blue competent E.coli (Stratagene).
  • Individual colonies are PCR amplified with M13 reverse and Ml 3-20 primers, which flank the insert.
  • the PCR products were sequenced using the nested primers T3 and T7.
  • oligonucleotide linkers were ligated onto the DNA fragments. Using primers directed against sites within these oligos the DNA fragments were amplified by PCR.
  • the Inker ligation reaction mix was set up as follows. 1 of sonicated BAC DNA. 5 ⁇ l 31 T4 DNA ligase (400 units / ⁇ l NEB). 5 ⁇ l 10 x ligase buffer. 2 ⁇ l linkers. 37.5 ⁇ l double distilled water, and incubated for 8 hours at 21 °C. PCR amplification was performed using 50 p. moles linker primers. 1 x buffer (Promega).
  • Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurones, and is re-expressed following axotomy. J. Neurophysiol.. 72. 466-470.
  • PGE 2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. J. Physiol. 495. 429-440.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un canal à ions sodium potentiel-dépendant, que l'on trouve en particulier dans le sous-groupe de faible diamètre de neurones sensoriels mammifères, ce nouveau canal étant ci-après dénommé SNS2a (canal spécifique 2a aux neurones sensoriels). L'invention concerne également les nucléotides codant pour ce canal, les vecteurs et les cellules hôtes contenant ce dernier, et des méthodes permettant de cribler ce canal de manière à identifier des modulateurs pouvant être utilisés pour soulager la douleur et/ou traiter les pathologies d'hypersensibilité.
PCT/GB1999/000838 1998-03-18 1999-03-18 Proteines mammiferes a canal sodique WO1999047670A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99910530A EP1062334A1 (fr) 1998-03-18 1999-03-18 Proteines mammiferes a canal sodique
AU29463/99A AU2946399A (en) 1998-03-18 1999-03-18 Mammalian sodium channel proteins
JP2000536853A JP2002508941A (ja) 1998-03-18 1999-03-18 哺乳動物ナトリウムチャンネル蛋白質

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9805793.8 1998-03-18
GBGB9805793.8A GB9805793D0 (en) 1998-03-18 1998-03-18 Sodium ion channels

Publications (1)

Publication Number Publication Date
WO1999047670A1 true WO1999047670A1 (fr) 1999-09-23

Family

ID=10828811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000838 WO1999047670A1 (fr) 1998-03-18 1999-03-18 Proteines mammiferes a canal sodique

Country Status (5)

Country Link
EP (1) EP1062334A1 (fr)
JP (1) JP2002508941A (fr)
AU (1) AU2946399A (fr)
GB (1) GB9805793D0 (fr)
WO (1) WO1999047670A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068681A3 (fr) * 2000-03-14 2002-01-24 Glaxo Group Ltd Proteines de canal ionique modifiees
WO2002002608A3 (fr) * 2000-07-05 2002-05-10 Neurosearch As Nouveau canal sodique (rnav1.5a) et utilisation
WO2002036747A3 (fr) * 2000-11-06 2002-11-07 Boehringer Ingelheim Int Canaux sodiques de type nerf peripherique
EP1053250A4 (fr) * 1998-01-29 2003-04-09 Univ Yale Modulation de canaux sodiques dans les ganglions spinaux
US6573067B1 (en) 1998-01-29 2003-06-03 Yale University Nucleic acid encoding sodium channels in dorsal root ganglia
WO2002040541A3 (fr) * 2000-10-27 2003-07-10 Incyte Genomics Inc Transporteurs et canaux a ions
US7125676B2 (en) 2002-02-25 2006-10-24 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
US20130102757A1 (en) * 2000-04-14 2013-04-25 Danisco Us Inc. Methods for selective targeting

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001577A1 (fr) * 1995-06-28 1997-01-16 University College London Canal ionique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001577A1 (fr) * 1995-06-28 1997-01-16 University College London Canal ionique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002110599, Database accession no. AA446878 *
DIB-HAJJ S. D. ET AL.: "NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy.", PROC. NATL. ACAD. SCI. U.S.A., vol. 95, July 1998 (1998-07-01), pages 8963 - 8968, XP002110597 *
TATE S. ET AL.: "Two sodium channels contribute to the TTX-R sodium current in prinary sensory neurons.", NATURE NEUROSCIENCE, vol. 1, no. 8, December 1998 (1998-12-01), pages 653 - 655, XP002110598 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053250A4 (fr) * 1998-01-29 2003-04-09 Univ Yale Modulation de canaux sodiques dans les ganglions spinaux
US6573067B1 (en) 1998-01-29 2003-06-03 Yale University Nucleic acid encoding sodium channels in dorsal root ganglia
US7067629B2 (en) 1998-01-29 2006-06-27 Yale University Sodium channel in dorsal root ganglia
US7829672B2 (en) 1998-01-29 2010-11-09 Yale University Modulation of sodium channels in dorsal root ganglia
WO2001068681A3 (fr) * 2000-03-14 2002-01-24 Glaxo Group Ltd Proteines de canal ionique modifiees
US20130102757A1 (en) * 2000-04-14 2013-04-25 Danisco Us Inc. Methods for selective targeting
US8779091B2 (en) * 2000-04-14 2014-07-15 Danisco Us Inc. Methods for selective targeting
WO2002002608A3 (fr) * 2000-07-05 2002-05-10 Neurosearch As Nouveau canal sodique (rnav1.5a) et utilisation
US7423121B2 (en) 2000-07-05 2008-09-09 Neurosearch A/S Sodium channel rNav1.5a
WO2002040541A3 (fr) * 2000-10-27 2003-07-10 Incyte Genomics Inc Transporteurs et canaux a ions
WO2002036747A3 (fr) * 2000-11-06 2002-11-07 Boehringer Ingelheim Int Canaux sodiques de type nerf peripherique
US7125676B2 (en) 2002-02-25 2006-10-24 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1

Also Published As

Publication number Publication date
AU2946399A (en) 1999-10-11
JP2002508941A (ja) 2002-03-26
EP1062334A1 (fr) 2000-12-27
GB9805793D0 (en) 1998-05-13

Similar Documents

Publication Publication Date Title
SK287323B6 (sk) Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie
JPH10229887A (ja) 神経ペプチドレセプターｈｆｇａｎ７２の新規なリガンド
JPH10510422A (ja) チロシンリン酸化タンパク質に結合する新規なタンパク質ドメイン
US5397702A (en) Assay for and treatment of autoimmune diseases
WO1999047670A1 (fr) Proteines mammiferes a canal sodique
US6207422B1 (en) Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the same
JP2000083669A (ja) Ｃｘｃｒ４ケモカイン受容体のヒトスプライス変異体ｃｘｃｒ４ｂ
DE69535590T2 (de) Für den bradykinin-b1-rezeptor kodierende dna
AU758011B2 (en) Persephin and related growth factors
JPH11235184A (ja) ヒト７回膜貫通受容体をコードするｃＤＮＡクローンＨＮＥＡＡ８ １
JP2003529337A (ja) ヒトアルファ１ｇ−ｃｔ型カルシウムチャンネルをコードするｄｎａ
JP4447783B2 (ja) 新規なぺプチド類
WO1993023538A1 (fr) Recepteurs de proteines isolees, anticorps se fixant a ces proteines, sequence d'acides nucleiques codant pour ces recepteurs, et leur applications
JP2002504492A (ja) Ｇタンパク質共役型受容体Ｆｉｓｈｂｏｙ
JP2002505872A (ja) ７回膜貫通ｇタンパク質共役受容体ｅｃｒ６７３
DE60132571T2 (de) Für den menschlichen vanilloid-rezeptor vr3 kodierende dns
DE60033297T2 (de) Für die humane untereinheit 5-ht3-c des serotoninrezeptors 5-ht3 kodierende dna
US5998579A (en) Epimorphin antagonist and process for producing it
US6664229B2 (en) Methods for treatment using novel ligands of the neuropeptide receptor HFGAN72
EP0977848B1 (fr) Sous-unite theta humaine du recepteur de gaba-a
US6794500B2 (en) RNA-binding protein
WO1996036711A2 (fr) Homeoproteine specifique des ilots pancreatiques et regulatrice de la transcription de l'expression du gene de l'insuline
JPH11206391A (ja) ヒトｌｉｇ−１相同体（ｈｌｉｇ−１）
JP2002511388A (ja) ヒトｇタンパク質共役受容体（ｇｐｒ２５）
DE60123943T2 (de) Ligandengesteuerte ionenkanäle aus dermacentor variabilis codierende dns-moleküle

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09646224

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999910530

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999910530

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999910530

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载